LA MEDICACION DOPAMINERGICA PODRIA SER UTIL PARA TRATAR TRASTORNOS CARDIOVASCULARES
Artículos relacionadosArtículos relacionadosArtículos relacionados
Artículos afines de siicsalud publicados en los últimos 4 meses
PATRONES DE MODIFICACIÓN DE TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE PARKINSON
Clinical Parkinsonism & Related Disorders 6(100125):1-7
Difundido en siicsalud: 11 may 2022

LA MEDICACION DOPAMINERGICA PODRIA SER UTIL PARA TRATAR TRASTORNOS CARDIOVASCULARES

(especial para SIIC © Derechos reservados)
Los pacientes con enfermedad de Parkinson presentan una reducción de los factores de riesgo vascular, atribuida a una desnervación simpática generalizada y a la estimulación central y periférica de los receptores D1/D2 por el tratamiento con L-dopa.
Autor:
Giulio Scigliano
Columnista Experto de SIIC

Institución:
Fondazione Istituto Nazionale Neurologico "C. Besta"


Artículos publicados por Giulio Scigliano
Coautores
Gabriele Ronchetti* Floriano Girotti* 
MD, Fondazione Istituto Nazionale Neurologico "C. Besta", Milán, Italia*
Recepción del artículo
16 de Marzo, 2009
Aprobación
1 de Abril, 2009
Primera edición
9 de Octubre, 2009
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
Realizamos un estudio de casos y controles con 483 pacientes consecutivos con enfermedad de Parkinson idiopática (EP) y 533 controles apareados por edad y sexo con el fin de investigar la relación entre la EP y los factores de riesgo para enfermedades cardiovasculares. Mediante análisis multivariado, la diabetes, la hipertensión, los antecedentes de tabaquismo, colesterol elevado y altos niveles de triglicéridos fueron significativamente menos frecuentes en la EP que en los controles. Además, estas asociaciones resultaban más evidentes para los pacientes tratados con L-dopa. Interpretamos esta asociación entre EP y reducción de los factores de riesgo vascular como debidos a insuficiencia en el eje hipotalámico-hipofisario-suprarrenal, desnervación simpática generalizada en la EP y estimulación central o periférica de los receptores dopamínicos D1 y D2 por la L-dopa. Estos efectos cardiovasculares y metabólicos favorables sugieren que la medicación dopaminérgica puede resultar útil en el tratamiento de los trastornos cardiovasculares.

Palabras clave
enfermedad de Parkinson, diabetes, hipertensión, colesterol, triglicéridos


Artículo completo

(castellano)
Extensión:  +/-9.72 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
We performed a case-control study on 483 consecutive patients with idiopathic Parkinson's disease (PD) and 533 age- and sex-matched controls to investigate the relationship between PD and risk factors for vascular diseases. Diabetes, high blood pressure, a history of cigarette smoking, high blood cholesterol, and high blood triglycerides were significantly less frequent in PD than in controls as studied by multivariable analysis. In addition, these associations were more evident for L-dopa-treated PD cases. We interpreted the association between PD and reduced risk factors for vascular disease as due to (a) impaired hypothalamic-pituitary-adrenal axis, (b) generalized sympathetic denervation in PD, and (c) central and peripheral stimulation of D1 and D2 dopamine receptors by L-dopa. These favorable metabolic and cardiovascular effects suggest that dopaminergic medication may be useful as therapy for cardiovascular disorders.

Key words
Parkinson disease, diabetes, hypertension, cholesterol, triglycerides


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Neurología
Relacionadas: Atención Primaria, Bioquímica, Cardiología, Diabetología, Diagnóstico por Laboratorio, Geriatría, Medicina Interna



Comprar este artículo
Extensión: 9.72 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Giulio Scigliano, Fondazione Istituto Nazionale Neurologico "C. Besta" Department of Neurology, 20127, Via Padova 113, Milán, Italia
Patrocinio y reconocimiento:
Agradecimiento: a Don Ward, por su ayuda con la redacción en inglés.
Bibliografía del artículo

1. Jellinger K. Pathology of parkinsonism. In: Fahn S et al eds. Recent developments in Parkinson's disease. Raven Press, New York, pp. 33-66, 1986.
2. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 38(Suppl.2):2-7, 1997.
3. Goodman LS, Gillman A. The pharmacological basis of therapeutics. Section: Relationship between the nervous and the endocrine system. 11th edition. Brunton LL Ed. McGraw-Hill Press, New York, 2007.
4. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 43(5):533-49, 2000.
5. Ahren B. Autonomic regulation of islet hormone secretion-implications for health and disease. Diabetologia 43:393-410, 2000.
6. Ahren B, Wierup N, Sundler F. Neuropeptides and the regulation of islet function. Diabetes 55(Suppl.2):98-107, 2006.
7. Niijima A. Neural control of blood glucose level. Jpn J Physiol 36(5):827-41, 1986.
8. Attvall S, Fowelin J, von Schenck H, Lager I, Smith U. Insulin resistance in type 1 (insulin-dependent) diabetes following hypoglycaemia--evidence for the importance of beta-adrenergic stimulation. Diabetologia 30(9):691-7, 1987.
9. Yamaguchi N. Sympathoadrenal system in neuroendocrine control of glucose: mechanisms involved in the liver, pancreas, and adrenal gland under hemorrhagic and hypoglycemic stress. Can J Physiol Pharmacol 70(2):167-206, 1992.
10. Jackson PA, Pagliassotti MJ, Shiota M, Neal DW, Cardin S, Cherrington AD. Effects of vagal blockade on counterregulatory response to insulin-induced hypoglycemia in the dog. Am J Physiol 273:1178-88, 1997.
11. Fabris SE, Thorburn A, Litchfield A, Proietto J. Effect of parasympathetic denervation of liver and pancreas on glucose kinetics in man. Metabolism 45(8):987-91, 1996.
12. Palatini P, Longo D, Zaetta V, Perkovic D, Garbelotto R, Pessina AC. Evolution of blood pressure and cholesterol in stage 1 hypertension: role of autonomic nervous system activity. J Hypertens 24(7):1375-81, 2006.
13. O'Donnell L, Owens D, McGee C, et al. Effects of catecholamines on serum lipoproteins of normally fed and cholesterol-fed rabbits. Metabolism 37(10):910-5, 1988.
14. O'Meara NM, Devery RA, Owens D, Collins PB, Johnson AH, Tomkin GH. Alterations in cellular cholesterol metabolism following administration of 6-hydroxydopamine to rabbits. Br J Pharmacol 105(2):495-9, 1992.
15. Scott LM, Tomkin GH. Cholesterol metabolism: regulatory effects of the vagus in the normal and diabetic animal. Diabetes Res 2(6):313-7, 1985.
16. Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 58:1247-55, 2002.
17. Camerlingo M, Aillon C, Bottacchi E, et al. Parasympathetic assessment in Parkinson's disease. Adv Neurol 45:267-9, 1987.
18. Oka H, Mochio S, Onouchi K, Morita M, Yoshioka M, Inoue K. Cardiovascular dysautonomia in de novo Parkinson's disease. J Neurol Sci 241(1-2):59-65, 2006.
19. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2(11):669-76, 2003.
20. Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 63(5):584-9, 1997.
21. Barbeau A, Gillo Joffroy L, Boucher R, Novaczynski W, Genest J. Renin-Aldosterone system in Parkinson's disease. Science 165:291-2, 1969.
22. Bellomo G, Santambrogio L, Fiacconi M, Scarponi AM, Ciuffetti G. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's disease. J Neurol 238(1):19-22, 1991.
23. Carmichael SW, Wilson RJ, Brimijoin WS, et al. Decreased catecholamines in the adrenal medulla of patients with parkinsonism. N Engl J Med 28:254, 1988.
24. Paquot N, Schneiter P, Jequier E, Tappy L. Effects of glucocorticoids and sympathomimetics agents on basal and insulin-stimulated glucose metabolism. Clin Physiol 15(3):231-40, 1995.
25. Goldstein DS, Robertson D, Esler M, Straus SE, Eisenhofer G. Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med 137(9):753-63, 2002.
26. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37:1184-8, 2006.
27. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 17:427-42, 1967.
28. Mannelli M, Gheri RG, Selli C, et al. A study on human adrenal secretion. Measurement of epinephrine, norepinephrine, dopamine and cortisol in peripheral and adrenal venous blood under surgical stress. J Endocrinol Invest 5(2):91-5, 1982.
29. Rahn KH, Barenbrock M, Hausberg M. The sympathetic nervous system in the pathogenesis of hypertension. J Hypertension 17(S 3):11-14, 1999.
30. Fratiglioni L, Wang XH. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav Brain Res 113(1-2):117-20, 2000.
31. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid concentrations: an analysis of published data. BMJ 298(6676):784-8, 1989.
32. Mannelli M, Pupili C, Lanzillotti R, Ianni L, Bellini F, Sergio M. Role of endogenous dopamine in modulating sympathetic-adrenal activity in humans. Hypertens Res 18(Suppl.1):79-86, 1995.
33. Whitsett TL, Halushka PV, Goldberg LI. Attenuation of postganglionic sympathetic nerve activity by L-dopa. Circ Res 27:561-70, 1970.
34. Murphy MB. Dopamine: a role in the pathogenesis and treatment of hypertension. J Hum Hypertens 14(1):S47-50, 2000.
35. Finlay GD, Whitsett TL, Cucinell EA, Goldberg L. Augmentation of sodium and potassium excretion, glomerular filtration rate and renal plasma flow by levodopa. N Engl J Med 284:865-870, 1971.
36. Sowers JR, Beck FW. Dopaminergic regulation of 18-hydroxycorticosterone and aldosterone secretion in man. Acta Endocrinol (Copenh) 102(2):258-64, 1983.
37. Barbieri C, Caldara R, Ferrari C, Crossignani RM, Recchia M. Inhibition of the renin-angiotensin-aldosterone system by L-dopa with and without inhibition of extracerebral dopa decarboxylase in man. Clin Sci (Lond) 61(2):187-90, 1981.
38. Golda V, Hilgertova J. Effect of terguride on insulin binding, insulinaemia, glucose tolerance and hyperlipaemia in lean SHR Koletsky rats. Physiol Res 46(6):439-42, 1997.
39. Cincotta AH, Meier AH, Cincotta Jr M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 8(10):1683-1707, 1999.
40. Saito I , Kawabe H, Hasegawa C, et al. Effect of L-dopa in young patients with hypertension. Angiology 42:691-5, 1991.
41. Dingemanse J, Kleinbloesem CH, Zurcher G, Wood ND, Crevoisier C. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br J Clin Pharmacol 44:41-8, 1997.
42. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37:1184-8, 2006.
43. Scigliano G, Ronchetti G, Girotti F, Musicco M. Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease. Park Rel Dis 15(2):138-43, 2009.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
Artículos relacionadosMás relacionadosAtículos relacionados
FÁRMACOS DOPAMINÉRGICOS EN EL INICIO DE LA ENFERMEDAD DE PARKINSON
Neurology 97(20):942-957
Difundido en siicsalud: 12 abr 2022
ua31618